ISSN:
1432-0584
Keywords:
Key words Acyclic retinoid
;
Acute promyelocytic leukemia (APL)
;
Differentiation therapy
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Acyclic retinoid (all-trans-3, 7, 11, 15-tetramethyl-2, 4, 6, 10, 14-hexadecapentaenoic acid) binds cellular retinoic acid-binding protein with an affinity similar to that of all-trans retinoic acid and induces differentiation of human hepatoma cell lines and a human acute myelogenous leukemia cell line (HL-60). We investigated the in vitro efficacy of acyclic retinoid to induce the differentiation of acute promyelocytic leukemia (APL) cells using primary cultured cells obtained from 11 APL patients. Five days' incubation with acyclic retinoid effected a dose-dependent induction of differentiation. Cells from eight patients showed maximum differentiation at 10–6 M acyclic retinoid. Cells from one patient required 10–5 M for maximum differentiation, while those from two patients exhibited moderate differentiation at 10–5 M. Five days' incubation with acyclic retinoid (10–7∼10–5 M) did not affect the viability or number of cells from any patient except one, whose cells showed a slight decrease in viability at 10–5 M. Thus, we conclude that acyclic retinoid induced the differentiation of primary cultured APL cells at concentrations of 10–6∼10–5 M, a range at which it is not toxic.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/s002770050232
Permalink
